Steve Riedmuller

Steve Riedmuller is a distinguished professional with a career spanning significant contributions to biotechnology and life sciences. Beginning at TIGR, he pioneered advancements in Sanger Sequencing process development and laboratory automation, laying a solid foundation for his subsequent roles.

As VP of Engineering at Hudson Robotics, Steven led the development of fully automated synthetic biology foundries tailored for the USDA and pharmaceutical applications. His expertise led to pivotal projects such as the Digital to Biological Converter and prototypes of the BioXP DNA Printer. He then joined SGI-DNA, leading the BioXP field applications team, and shaped the DNA library product portfolio.

Steven's leadership was instrumental in revitalizing Maxygen as CEO, focusing on molecular breeding to accelerate protein and enzyme evolution. His strategic acumen further shone as Chief Commercial Officer at Swift BioSciences, where he successfully enhanced commercial performance, ultimately facilitating the company's acquisition by IDT.

With a passion for innovation, Steven founded NinthBio, concentrating on developing software tools that streamline DNA assembly processes. Currently, as VP of Commercial Operations at Neochromosome, he is tasked with commercializing their advancements in engineering yeast as a bioproduction and antibody discovery tool, DNA and NGS services.

Throughout his career, Steven Riedmuller has consistently demonstrated a commitment to pushing the boundaries of biotechnology, leveraging his expertise to drive transformative impact in the field.